Weekly Marketing Briefing: Cosentyx

Week ending August 16, 2026

1. How AI is currently framing the brand

AI answers frame Cosentyx in a largely neutral, clinical, shared-decision-making context rather than as a clear market leader. Brand answers repeatedly describe it as an IL-17A inhibitor and emphasize “patient-specific fit,” dosing, access, mechanism, and safety considerations. The tone is highly cautious: 99 hedging/disclaimer instances and 78 infection-risk references appeared this week. Excerpts commonly use language such as “both options are reasonable,” “individual experiences vary,” and “the choice usually depends on your priorities.”

2. Share of voice vs. named competitors

Competitor mentions declined across the board as response volume fell from 140 to 120, but competitors remain prominent inside Cosentyx answers:

• Taltz: 10 mentions, down from 17
• Humira: 9, down from 16
• Stelara: 9, down from 16
• Enbrel: 8, down from 15
• Tremfya: 2, up from 1; Skyrizi: 1, down from 3

No major competitor is gaining ground in absolute terms. Taltz remains the leading named competitor, triggered most directly by “choosing Cosentyx versus Taltz” and switching-from-another-IL-17 questions. Humira appears in effectiveness and side-effect comparisons; Stelara in practical differences involving mechanism, dosing, and monitoring; Enbrel in “is Cosentyx stronger?” questions.

The opportunity is not simply to suppress competitor mentions: answers often position Cosentyx as one of several “good” biologic options, leaving limited brand-owned explanation of why its attributes may matter.

3. Messaging consistency and content gaps

The largest gap is precision and consistency in practical information:

• Dosing: Answers disagree on whether plaque-psoriasis loading is four or five weekly doses and whether maintenance begins at Week 4 or Week 5.
• Safety labeling: In the boxed-warning question, five answers say there is no U.S. boxed warning while one says Cosentyx has one. This is a material accuracy and trust issue.
• Indications and age groups: Answers vary on pediatric eligibility and regional labeling.
• Administration: Multiple answers mention pen, syringe, and IV options, but device-specific handling guidance varies.

These gaps support a prioritized SEO content program: an authoritative, indication-specific dosing hub; device/formulation administration pages; a plain-language “boxed warning vs. important safety information” explainer; and region-labeled pediatric, pregnancy/lactation, and vaccine guidance. Each should clearly distinguish U.S. prescribing information from general or non-U.S. guidance.

4. Overclaim / compliance-adjacent language watch

There were 28 overclaim-language instances, including “best,” “stronger,” “superior,” “most effective,” “number one,” and “strongest.” These are appearing in AI-generated answers—not necessarily in company marketing—but warrant review because they can create unsupported superiority impressions. The “stronger than Enbrel” question is especially prone to this framing, even though most answers correctly redirect toward “different mechanisms” and patient fit.

5. Recommended actions

1. Commission an evidence-reviewed Cosentyx dosing and administration hub. Resolve the four-versus-five-dose variation, device differences, storage, and missed-dose questions using current local labeling.
2. Publish a clear safety-label explainer. Directly address boxed warnings, infection/TB screening, IBD considerations, live vaccines, and hypersensitivity; this targets the 24 inconsistency flags and the contradictory boxed-warning answers.
3. Build comparison pages for Taltz, Humira, Stelara, and Enbrel. Use neutral, indication-specific tables covering mechanism, dosing, practical considerations, and safety—not “stronger/best” language.
4. Create a switching and access resource. AI repeatedly identifies prior authorization, formulary status, onset expectations, and tolerability as real-world discussion points.
5. Add region-specific patient FAQs for pediatric use, pregnancy/lactation, renal/hepatic impairment, and biosimilar substitution.